Acadia Pharmaceuticals Inc.
—Price / book
Market cap
—
Tangible equity (USD)
—
Price / tangible book
—
Price / book
—
Net income / ending equity
31.9%
Net income / ending assets
25.0%
Efficiency ratio
—
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ACAD stock price vs ZION: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZION's multiple
Needs ZION P/E.
Implied fair value · at ACAD's multiple
Needs ACAD P/E.
Price unavailable
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability edge
Asset efficiency edge
Lower is better
Statements
Reported bank earnings and balances, with each company’s reporting period shown.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity (USD)
—
Price / tangible book
—
Price / book
—
Net income / ending equity
31.9%
Net income / ending assets
25.0%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity (USD)
$6.09B
Price / tangible book
—
Price / book
—
Net income / ending equity
12.5%
Net income / ending assets
1.0%
Efficiency ratio
323.0%
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ACADIA PHARMACEUTICALS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ZIONS BANCORPORATION, NATIONAL ASSOCIATION · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ACAD vs SUPN
Sage Therapeutics, Inc.
ACAD vs SAGE
Jazz Pharmaceuticals plc
ACAD vs JAZZ
Alkermes plc.
ACAD vs ALKS
Harmony Biosciences Holdings, Inc.
ACAD vs HRMY
Krystal Biotech, Inc.
ACAD vs KRYS
Wells Fargo & Company
ACAD vs WFC
JPMorgan Chase & Co.
ACAD vs JPM
Citizens Financial Group, Inc.
ACAD vs CFG
Huntington Bancshares Incorporated
ACAD vs HBAN
KeyCorp
ACAD vs KEY
Comerica Incorporated
ACAD vs CMA
First Citizens BancShares, Inc.
ACAD vs FCNCA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.